166 related articles for article (PubMed ID: 33064984)
21. Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes.
Gros A; Tran E; Parkhurst MR; Ilyas S; Pasetto A; Groh EM; Robbins PF; Yossef R; Garcia-Garijo A; Fajardo CA; Prickett TD; Jia L; Gartner JJ; Ray S; Ngo L; Wunderllich JR; Yang JC; Rosenberg SA
J Clin Invest; 2019 Nov; 129(11):4992-5004. PubMed ID: 31609250
[TBL] [Abstract][Full Text] [Related]
22. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
[TBL] [Abstract][Full Text] [Related]
23. Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies.
Kast F; Klein C; Umaña P; Gros A; Gasser S
Oncoimmunology; 2021 Jan; 10(1):1869389. PubMed ID: 33520408
[TBL] [Abstract][Full Text] [Related]
24. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
25. Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine.
Liu CJ; Schaettler M; Blaha DT; Bowman-Kirigin JA; Kobayashi DK; Livingstone AJ; Bender D; Miller CA; Kranz DM; Johanns TM; Dunn GP
Neuro Oncol; 2020 Sep; 22(9):1276-1288. PubMed ID: 32133512
[TBL] [Abstract][Full Text] [Related]
26. Toward in silico Identification of Tumor Neoantigens in Immunotherapy.
Zhou C; Zhu C; Liu Q
Trends Mol Med; 2019 Nov; 25(11):980-992. PubMed ID: 31494024
[TBL] [Abstract][Full Text] [Related]
27. Uncloaking Breast Tumor Neoantigens with Radiation.
Newman JH; Bhardwaj N
Trends Immunol; 2021 Apr; 42(4):277-279. PubMed ID: 33674225
[TBL] [Abstract][Full Text] [Related]
28. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.
Carreno BM; Magrini V; Becker-Hapak M; Kaabinejadian S; Hundal J; Petti AA; Ly A; Lie WR; Hildebrand WH; Mardis ER; Linette GP
Science; 2015 May; 348(6236):803-8. PubMed ID: 25837513
[TBL] [Abstract][Full Text] [Related]
29. TruNeo: an integrated pipeline improves personalized true tumor neoantigen identification.
Tang Y; Wang Y; Wang J; Li M; Peng L; Wei G; Zhang Y; Li J; Gao Z
BMC Bioinformatics; 2020 Nov; 21(1):532. PubMed ID: 33208106
[TBL] [Abstract][Full Text] [Related]
30. Neoantigen landscape dynamics during human melanoma-T cell interactions.
Verdegaal EM; de Miranda NF; Visser M; Harryvan T; van Buuren MM; Andersen RS; Hadrup SR; van der Minne CE; Schotte R; Spits H; Haanen JB; Kapiteijn EH; Schumacher TN; van der Burg SH
Nature; 2016 Aug; 536(7614):91-5. PubMed ID: 27350335
[TBL] [Abstract][Full Text] [Related]
31. Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma.
Bräunlein E; Lupoli G; Füchsl F; Abualrous ET; de Andrade Krätzig N; Gosmann D; Wietbrock L; Lange S; Engleitner T; Lan H; Audehm S; Effenberger M; Boxberg M; Steiger K; Chang Y; Yu K; Atay C; Bassermann F; Weichert W; Busch DH; Rad R; Freund C; Antes I; Krackhardt AM
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518289
[TBL] [Abstract][Full Text] [Related]
32. Personalized combination nano-immunotherapy for robust induction and tumor infiltration of CD8
Park KS; Nam J; Son S; Moon JJ
Biomaterials; 2021 Jul; 274():120844. PubMed ID: 33962217
[TBL] [Abstract][Full Text] [Related]
33. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.
Chen Z; Zhang S; Han N; Jiang J; Xu Y; Ma D; Lu L; Guo X; Qiu M; Huang Q; Wang H; Mo F; Chen S; Yang L
Front Immunol; 2021; 12():691605. PubMed ID: 34484187
[TBL] [Abstract][Full Text] [Related]
34. Cancer neoantigens targeted by adoptive T cell transfer: private no more.
Lugli E; Kvistborg P; Galletti G
J Clin Invest; 2019 Mar; 129(3):949-951. PubMed ID: 30714989
[TBL] [Abstract][Full Text] [Related]
35. A proteogenomic approach to target neoantigens in solid tumors.
Verma A; Halder A; Marathe S; Purwar R; Srivastava S
Expert Rev Proteomics; 2020; 17(11-12):797-812. PubMed ID: 33491499
[TBL] [Abstract][Full Text] [Related]
36. Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8
Fehlings M; Simoni Y; Penny HL; Becht E; Loh CY; Gubin MM; Ward JP; Wong SC; Schreiber RD; Newell EW
Nat Commun; 2017 Sep; 8(1):562. PubMed ID: 28916749
[TBL] [Abstract][Full Text] [Related]
37. Neoantigen Dissimilarity to the Self-Proteome Predicts Immunogenicity and Response to Immune Checkpoint Blockade.
Richman LP; Vonderheide RH; Rech AJ
Cell Syst; 2019 Oct; 9(4):375-382.e4. PubMed ID: 31606370
[TBL] [Abstract][Full Text] [Related]
38. Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab.
Veatch JR; Singhi N; Jesernig B; Paulson KG; Zalevsky J; Iaccucci E; Tykodi SS; Riddell SR
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33298619
[TBL] [Abstract][Full Text] [Related]
39. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
[TBL] [Abstract][Full Text] [Related]
40. Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies.
Lo AA; Wallace A; Oreper D; Lounsbury N; Havnar C; Pechuan-Jorge X; Wu TD; Bourgon R; Jones R; Krogh K; Yang GY; Zill OA
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
